drugset / Trial / NCT00632242
ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the overall safety and tolerability of ARC1779, a therapeutic oligonucleotide ("aptamer") in patients with three types of von Willebrand Factor related platelet disorders.
Timeline
- Start
- 2008-01
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Desmopressin | Peptide | 0.4 ug/kg | Other |
| Subject | EGAPTIVON PEGOL | Aptamer | 0.24 mg/kg | Other |
| Subject | EGAPTIVON PEGOL | Aptamer | 1.44 mg/kg | Other |
| Subject | EGAPTIVON PEGOL | Aptamer | 2.88 mg/kg | Other |
| Subject | EGAPTIVON PEGOL | Aptamer | 40.78 mg/kg | Other |